IN8bio, Inc. (NASDAQ:INAB) Short Interest Up 34.0% in November

IN8bio, Inc. (NASDAQ:INAB) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,340,000 shares, an increase of 34.0% from the October 31st total of 1,000,000 shares. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is presently 1.2 days. Currently, 2.7% of the company’s shares are short sold.

IN8bio Stock Performance

IN8bio stock opened at $0.30 on Friday. IN8bio has a fifty-two week low of $0.22 and a fifty-two week high of $2.48. The company has a market capitalization of $22.08 million, a PE ratio of -0.41 and a beta of -0.07. The company has a 50 day moving average price of $0.30 and a 200-day moving average price of $0.63. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84.

IN8bio (NASDAQ:INAB) last issued its earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, equities analysts forecast that IN8bio will post -0.56 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of IN8bio in a research report on Tuesday.

Institutional Trading of IN8bio

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp lifted its holdings in IN8bio, Inc. (NASDAQ:INAB) by 42.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 851,280 shares of the company’s stock after purchasing an additional 251,600 shares during the period. Sigma Planning Corp owned about 1.82% of IN8bio worth $230,000 at the end of the most recent quarter. 92.05% of the stock is owned by institutional investors.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.